Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,167 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00602030 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | completed | Phase 1 / Phase 2 | 141 | Syndax PharmaceuticalsINDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02862457 | Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2022 |
| clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT03438318 | Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | completed | Phase 1 | 29 | Regeneron PharmaceuticalsINDUSTRY | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02926768 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | completed | Phase 1 | 136 | Checkpoint Therapeutics, Inc.INDUSTRY | 5 | Jul 26, 2022 | clinicaltrials |
| NCT01014598 | Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis | completed | Phase 1 | 11 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03297424 | A Study of PLX2853 in Advanced Malignancies. | completed | Phase 1 | 49 | Opna Bio LLCINDUSTRY | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01854684 | Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery | completed | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03080311 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | completed | Phase 1 | 50 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02535325 | Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2022 | clinicaltrials |
| NCT03623750 | E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C(EPICAL) | completed | Phase 1 / Phase 2 | 23 | Instituto Oncológico Dr RosellOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT04507906 | Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | completed | Phase 1 / Phase 2 | 21 | Shanghai Chest HospitalOTHER | 1 | Jun 28, 2022 | clinicaltrials |
| NCT02648724 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Symphogen A/SINDUSTRY | 6 | Jun 22, 2022 | clinicaltrials |
| NCT04041011 | A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients | completed | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04315467 | Intraoperative Imaging of Pulmonary Nodules by SGM-101 | completed | Phase 1 | 10 | Sunil SinghalOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT00750269 | Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 120 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 9, 2022 | clinicaltrials |
| NCT03386955 | BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 215 | Beta Pharma ShanghaiINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT02470468 | Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer | completed | Phase 1 / Phase 2 | 105 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT03268057 | VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer(CLASSICAL-Lung) | completed | Phase 1 / Phase 2 | 62 | Vaccinex Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT02897778 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 1 | Apr 28, 2022 | clinicaltrials |
| NCT03562871 | IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | completed | Phase 1 / Phase 2 | 109 | IO BiotechINDUSTRY | 4 | Apr 21, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT02088112 | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | completed | Phase 1 | 56 | MedImmune LLCINDUSTRY | 3 | Apr 4, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02166242 | Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers | completed | Phase 1 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01061840 | Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer | completed | Phase 1 | 100 | Gradalis, Inc.INDUSTRY | 1 | Mar 15, 2022 | clinicaltrials |
| NCT02526017 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers(FPA008-003) | completed | Phase 1 | 313 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03773380 | Breathe Anew for Lung Cancer Survivorship(BA) | completed | Phase 1 | 50 | St. Joseph's Healthcare HamiltonOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | completed | Phase 1 | 24 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05226728 | Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer | completed | Phase 1 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT04316689 | First-in-human Study of S-588210 (S-488210+S-488211) | completed | Phase 1 | 10 | ShionogiINDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02909452 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 1 | Jan 25, 2022 | clinicaltrials |
| NCT02318277 | A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | completed | Phase 1 / Phase 2 | 176 | Incyte CorporationINDUSTRY | 1 | Jan 13, 2022 | clinicaltrials |
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02403193 | Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(AdenONCO) | completed | Phase 1 | 92 | Palobiofarma SLINDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03514719 | PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)(PINNACLE) | completed | Phase 1 | 24 | Radboud University Medical CenterOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Aug 22, 2022source: clinicaltrials